Adam Lenkowsky

Adam Lenkowsky is the general manager and head of U.S. Cardiovascular, Immunology and Oncology at Bristol Myers Squibb (BMS). In this role, he heads a business unit that in 2018 contributed 56% of the company’s $22.6 billion in revenue. He leads an organization of more than 2,500 employees that deliver transformational medicines such as Eliquis, Opdivo, Yervoy and Orencia. He is passionate about cultivating a culture that prioritizes its people, performance, customers and above all else - patients.

Adam’s full biopharma career extends more than 20 years across commercial, market access, sales, and operations. He has held a number of commercial leadership positions at BMS.